Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Entrada Therapeutics, Inc. (TRDA) is a Biotechnology company based in US with a market capitalization of $272.5M. Revenue declined 87.9% year-over-year and free cash flow was negative at -$129.6M. This page tracks TRDA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 183 employees · IPO Oct 29, 2021
Valuation
Valuation & price
$6.38as of May 17, 2026· -60.2% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.89
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$272.5M
Market cap
-87.9%
Revenue growth (YoY)
83.9%
Gross margin
-$129.6M
Free cash flow (USD)
-$244.8M
Net debt
Net cash position
10.9%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2019 → 2025
Free cash flow by year
2019 → 2025
Gross margin by year
2023 → 2025
Value screen
Graham defensive-investor tests
1
Insider buys · 90 days
2
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 7, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJun 10, 2026Filing
Annual Meeting Results
- Insider buyMay 21, 2026Filing
Insider Buy $29KZeiher Bernhardt G · Director · $29.3K
- 8-K eventMay 19, 2026Filing
Corporate Presentation
- 8-K eventMay 7, 2026Filing
Earnings Release
- Quarterly reportMay 7, 2026Filing
10-Q Filed
- Insider sellMay 4, 2026Filing
Insider Sell $230K · 10b5-1 PlanDowden Nathan J · President & COO · $230K
- Insider sellMay 4, 2026Filing
Insider Sell $399K · 10b5-1 PlanSethuraman Natarajan · President, Research & Develop. · $398.8K
- Insider sellApr 2, 2026Filing
Insider Sell $32K · 10b5-1 PlanWENTWORTH KORY JAMES · Chief Financial Officer · $32.4K
Questions
Frequently asked questions
What is Entrada Therapeutics, Inc.'s market cap?
Entrada Therapeutics, Inc. (TRDA) has a market capitalization of $272.5M.
What is TRDA's P/E ratio?
A meaningful P/E ratio is not available for TRDA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is TRDA's price-to-book (P/B) ratio?
TRDA trades at 0.89 times book value per share.
Are insiders buying TRDA stock?
Yes — SEC Form 4 filings show 1 open-market insider buy and 2 sells at Entrada Therapeutics, Inc. in the last 90 days.
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.